We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CMO Concerns Draw CRL for Navidea’s Lymphoseek
CMO Concerns Draw CRL for Navidea’s Lymphoseek
September 14, 2012
The FDA has sent Navidea a complete response letter (CRL) on its Lymphoseek injection, citing concerns over quality control at third-party contract manufacturing facilities.